Page 145 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

PET improves DLBCL response predictors
Supplemental materials
Supplemental Table 1. Uni- and multivariable Cox Proportional Hazard analyses including baseline MTV for 2-year PFS (n=296).
Age (≤60 vs >60)
aaIPI (low/low-intermediate vs high-intermediate/high)
B symptoms (no vs yes)
Baseline MTV log-transformed
∆SUVmax (>70% vs ≤70%)
Gender (male vs female)
Treatment arm (R-CHOP14 vs RR-CHOP14
* Statistically significant difference
2-year PFS
1·44 (0·80-2·59) 2·83 (1·50-5·34)
1·97 (1·18-3·30) 1·43 (1·16-1·76) 7·44 (4·29-12·92) 0·73 (0·44-1·23) 0·85 (0·51-1·42)
0·222 1·83 (1·01-3·32) 0·001*
0·010* 1·75 (1·04-2·98) 0·001* 1·32 (1·07-1·62) <0·0001* 7·87 (4·48-13·83) 0·240
0·539
0·046
0·036 0·010 <0·0001*
Univariate P-value Multivariable P-value HR (95%CI) HR (95%CI)
Abbreviations: 95%CI= 95% confidence interval; aaIPI= age-adjusted international prognostic index; HR= Hazard Ratio; LDH= lactate dehydrogenase; MTV=metabolic tumor volume; PFS= progression-free survival; WHO= world health organization.
Supplemental Table 2. I-PET4 and EoT-PET 2x2 contingency table.
I-PET4 positive (DS 4-5) I-PET4 negative (DS 1-3) Total
EoT-PET positive (DS 4-5)
54 20^ 74 *
EoT-PET negative Total (DS 1-3)
42~ 96 358 378 400 † 474
Abbreviations: DS= Deauville 5-point scale; EoT-PET= end-of-treatment 18F-FDG PET(/CT); I-PET4= interim 18F-FDG PET(/CT) after four treatment cycles.
*No I-PET4 was performed in 5 patients with positive EoT-PET (reasons unknown).
†No I-PET4 was performed in 14 patients with negative EoT-PET(reasons unknown), in 3 patients I-PET4 was not available for qualitative analysis (high glucose, poor visual quality and not interpretable due to missing baseline scan, respectively).
^ Twenty patients (4.2%) switched from a negative I-PET4 to a positive EoT-PET, sixteen of these patients had a high-intermediate or high aaIPI and had a 2-year PFS of 40% (95%CI 18-62%).
~ Forty-two patients (8.9%) had a positive I-PET4 and turned negative at EoT-PET, of these only 4 patients had progressive disease within 2 years after randomization of whom 2 died within this period. These converting patients had a 2-year PFS of 90% (95%CI 81-99%).
143
6a